Biotech giant Amgen signed an agreement with Belgium-based Biocartis Group to assist in the development of companion diagnostic tests for its colorectal cancer drug Vectibix. The Thousand Oaks-based company has partnered with Biocartis to develop its Idylla platform, which uses biomarkers to predict whether a treatment will be effective for a particular patient, since February…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
